BioScrip, Inc. (BIOS) EPS Estimated At $-0.10

July 14, 2018 - By Michael Garrison

BioScrip, Inc. (NASDAQ:BIOS) LogoInvestors sentiment increased to 1.39 in 2018 Q1. Its up 0.21, from 1.18 in 2017Q4. It is positive, as 10 investors sold BioScrip, Inc. shares while 26 reduced holdings. 16 funds opened positions while 34 raised stakes. 106.54 million shares or 2.37% more from 104.07 million shares in 2017Q4 were reported.
Venor Capital Management L P holds 14.65M shares or 21.73% of its portfolio. Wells Fargo & Mn owns 185,859 shares. Brighton Jones holds 0.01% or 22,851 shares in its portfolio. 175,971 were accumulated by California State Teachers Retirement System. 126,000 are held by Perkins Mgmt. First Republic Mgmt Inc has 0% invested in BioScrip, Inc. (NASDAQ:BIOS). State Board Of Administration Of Florida Retirement holds 0% of its portfolio in BioScrip, Inc. (NASDAQ:BIOS) for 67,104 shares. Janney Montgomery Scott Lc, Pennsylvania-based fund reported 15,528 shares. Roanoke Asset Mngmt Ny holds 0.48% or 403,280 shares in its portfolio. New York-based Tower Capital Ltd Com (Trc) has invested 0% in BioScrip, Inc. (NASDAQ:BIOS). Bnp Paribas Arbitrage Sa invested in 0% or 26,698 shares. Rhumbline Advisers holds 0% or 108,506 shares. 4.41 million are held by D E Shaw Inc. Amalgamated Comml Bank holds 15,226 shares or 0% of its portfolio. Salzhauer Michael accumulated 0.03% or 34,075 shares.

Analysts expect BioScrip, Inc. (NASDAQ:BIOS) to report $-0.10 EPS on August, 14.They anticipate $0.01 EPS change or 9.09 % from last quarter’s $-0.11 EPS. After having $-0.12 EPS previously, BioScrip, Inc.’s analysts see -16.67 % EPS growth. The stock decreased 4.76% or $0.15 during the last trading session, reaching $3. About 679,758 shares traded or 13.18% up from the average. BioScrip, Inc. (NASDAQ:BIOS) has risen 39.44% since July 14, 2017 and is uptrending. It has outperformed by 26.87% the S&P500.

BioScrip, Inc. (NASDAQ:BIOS) Ratings Coverage

Among 2 analysts covering BioScrip Inc (NASDAQ:BIOS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioScrip Inc has $3.5000 highest and $3.25 lowest target. $3.38’s average target is 12.67% above currents $3 stock price. BioScrip Inc had 2 analyst reports since March 8, 2018 according to SRatingsIntel. SunTrust maintained the stock with “Buy” rating in Thursday, March 8 report. The company was maintained on Wednesday, April 11 by Barrington.

BioScrip, Inc. provides home infusion services in the United States. The company has market cap of $383.86 million. The firm engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. It currently has negative earnings. It is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.

More news for BioScrip, Inc. (NASDAQ:BIOS) were recently published by: Globenewswire.com, which released: “BioScrip Appoints Richard Denness as Chief Commercial Officer” on July 10, 2018. Profitconfidential.com‘s article titled: “BIOS Stock Is All Set for an Explosive Move Toward Higher Prices” and published on July 09, 2018 is yet another important article.

BioScrip, Inc. (NASDAQ:BIOS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.